Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB EBITDA Margin
EBITDA as a percentage of revenue.
Nuvation Bio Inc.NYSE: NUVB
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to -175.3%
EBITDA Margin was -175.3% in Q2 FY2026, up 1029.5 pp from a year earlier. On a trailing-twelve-month basis it was -74.8%, up 1326.6 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -62.8% for the fiscal year ending Dec 2026, up from -300.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -175.3%-190.5 pp QoQ
- Last fiscal yearDec 2025
- -300.8%+6900.0 pp YoY
- LTMJun 2026
- -74.8%+1326.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1029.5 pp | +310.3 pp | -719.3 pp |
| 1 year | +6900.0 pp | +237.9 pp | -6662.0 pp |
| 3 years | — | +291.5 pp | — |
| 5 years | +330.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -300.8%
- Year-over-year change
- +6900.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -300.8% | +6900.0pp |
| FY2024 | 2024-12-31 | -7200.7% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 EBITDA Margin of -74.8% is the 2nd highest of the 8 companies compared; the peer median is -520.3%.
- Its year-over-year change of +1326.6 pp is the 2nd highest of 8, against a peer median of +27.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 60.4% | +27.2 pp | +122.5 pp | |
| LTM Jun 2026 | -74.8% | +1326.6 pp | — | |
| LTM Sep 2026 | -204.3% | +396.8 pp | -251.6 pp | |
| LTM Jun 2026 | -516.8% | +111160.6 pp | +6811.5 pp | |
| LTM Mar 2026 | -520.3% | +290.5 pp | -393.5 pp | |
| LTM Mar 2026 | -527.0% | -231.3 pp | -361.8 pp | |
| LTM Mar 2026 | -713.8% | -30.6 pp | -622.8 pp | |
| LTM Sep 2026 | -272652.7% | -264146.9 pp | -12607.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding NUVB) | -520.3% | +27.2 pp | -361.8 pp | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7.87M | 62.9M |
| Cost of Revenue | 0 | 0 | 0 | 7.08M | 8.44M |
| Gross Profit | 0 | 0 | 0 | 795K | 54.46M |
| Gross Margin | — | — | — | 10.1% | 86.6% |
| Research & Development | 69.04M | 87.82M | 71.29M | 524.19M | 115.11M |
| Selling, General & Admin | 24.28M | 31.92M | 28.53M | 69.23M | 151.56M |
| Operating Expenses | 93.32M | 119.73M | 99.82M | 593.42M | 267.52M |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| EBITDA | (86.66M) | (104M) | (75.58M) | (566.92M) | (189.21M) |
| EBITDA Margin | — | — | — | -7200.7% | -300.8% |
| Operating Income | (93.32M) | (119.73M) | (99.82M) | (592.63M) | (213.06M) |
| Operating Margin | — | — | — | -7527.3% | -338.7% |
| Interest Income | 2.96M | 7.45M | 24.61M | 27.06M | 21.43M |
| Interest Expense | 0 | 0 | 0 | 341K | 13.68M |
| Other Income / Expenses | 6.47M | 15.54M | 24.02M | 24.69M | 8.44M |
| Income Before Tax | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Pre-Tax Margin | — | — | — | -7213.8% | -325.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Net Margin | — | — | — | -7213.8% | -325.3% |
| EPS (Basic) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| EPS (Diluted) | (0.44) | (0.48) | (0.35) | (2.11) | (0.60) |
| Weighted Avg Shares | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
| Weighted Avg Shares (Diluted) | 197.89M | 216.72M | 218.88M | 268.77M | 341.54M |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.